APA (7th ed.) Citation

S, O., S, J., A, C., S, R., Y, O., C, E., . . . YK, B. (2026). PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma. Cell death & disease, 17(1), . https://doi.org/10.1038/s41419-026-08739-5

Chicago Style (17th ed.) Citation

S, Onishi, et al. "PRMT5 Inhibition Impairs Fanconi Anemia Pathway-mediated Homologous Recombination and Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma." Cell Death & Disease 17, no. 1 (2026). https://doi.org/10.1038/s41419-026-08739-5.

MLA (9th ed.) Citation

S, Onishi, et al. "PRMT5 Inhibition Impairs Fanconi Anemia Pathway-mediated Homologous Recombination and Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma." Cell Death & Disease, vol. 17, no. 1, 2026, https://doi.org/10.1038/s41419-026-08739-5.